Imatinib

Generic Name: Imatinib

Brand Names: Gleevec, Glivec, Imatinib Teva, Imatinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₁N_₇O

CAS Number: 152459-95-5

Unique Ingredient Identifier: BKJ8M8G5HI

Background: Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...

Indication: Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor

Associated Therapies: -

Clinical Trials

Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study

Phase 2

Completed

Conditions: Treatment
Stem Cell Transplantation

First Posted Date: 2009-12-03

Last Posted Date: 2022-10-12

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 40

Registration Number: NCT01025505

Locations: 🇮🇹
Osp. Reg. A. Di Summa, Brindisi, Italy
🇮🇹
Clinica Ematologica - Università degli Studi, Genova, Italy
🇮🇹
U.O. Ematologia, Azienda Ospedaliera Universitaria Senese, Siena, Italy

and more 32 locations

Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Dasatinib
Drug: Imatinib

First Posted Date: 2009-09-23

Last Posted Date: 2016-01-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 238

Registration Number: NCT00982488

Locations: 🇺🇸
Pacific Cancer Medical Center Inc, Anaheim, California, United States
🇺🇸
Ucla Department Of Medicine, Los Angeles, California, United States
🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States

and more 15 locations

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Prednisone
Drug: Vincristine
Drug: Doxorubicin
Drug: PEG-asparaginase
Drug: Cytarabine
Drug: Methotrexate
Drug: Imatinib
Drug: Clofarabine
Drug: 6 Mercaptopurine

First Posted Date: 2009-09-09

Last Posted Date: 2017-03-30

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 30

Registration Number: NCT00973752

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors

Phase 2

Completed

Conditions: Advanced Gastrointestinal Stromal Tumors

Interventions: Drug: Imatinib

First Posted Date: 2009-07-16

Last Posted Date: 2011-07-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 135

Registration Number: NCT00940563

Locations: 🇮🇹
Novartis Investigative Site, Verona, Italy

Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy

Phase 2

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Imatinib

First Posted Date: 2009-03-10

Last Posted Date: 2014-12-03

Lead Sponsor: Università degli Studi di Brescia

Target Recruit Count: 78

Registration Number: NCT00858806

Locations: 🇮🇹
Chair of Haematology, Bone Marrow Transplant Unit, Brescia, Italy

Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia

Phase 2

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Dasatinib
Drug: Imatinib

First Posted Date: 2009-02-27

Last Posted Date: 2017-09-25

Lead Sponsor: Norwegian University of Science and Technology

Target Recruit Count: 46

Registration Number: NCT00852566

Locations: 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇸🇪
Karolinska University Hospital, Stockholm, Sweden
🇸🇪
Uppsala University Hospital, Uppsala, Sweden

and more 4 locations

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Phase 3

Terminated

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Imatinib
Drug: Masitinib

First Posted Date: 2008-12-22

Last Posted Date: 2023-02-01

Lead Sponsor: AB Science

Target Recruit Count: 335

Registration Number: NCT00812240

Locations: 🇫🇷
Centre Val d'Aurèle, Montpellier, France
🇱🇧
Makassed General Hospital Tarik Jadide, Beirut, Lebanon
🇱🇧
Hôpital Saint-Georges, Beirut, Lebanon

and more 38 locations

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib

Phase 3

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: nilotinib
Drug: imatinib

First Posted Date: 2008-12-05

Last Posted Date: 2015-11-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 191

Registration Number: NCT00802841

Locations: 🇻🇪
Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela

Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes

Phase 2

Completed

Conditions: Hypereosinophilic Syndrome
Chronic Eosinophilic Leukemia
Chronic Idiopathic Hypereosinophilia

Interventions: Drug: Imatinib

First Posted Date: 2008-11-07

Last Posted Date: 2010-12-29

Lead Sponsor: Northern Italy Leukemia Group

Target Recruit Count: 25

Registration Number: NCT00787384

Locations: 🇮🇹
USC Ematologia Ospedali Riuniti di Bergamo, Bergamo, Italy
🇮🇹
Divisione di Ematologia Spedali Civili di Brescia, Brescia, Italy
🇮🇹
USC Ematologia Azienda Ospedaliera Università Careggi, Firenze, Italy

and more 1 locations

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

Phase 3

Completed

Conditions: CHRONIC MYELOGENOUS LEUKEMIA

Interventions: Drug: Nilotinib
Drug: Imatinib

First Posted Date: 2008-09-26

Last Posted Date: 2016-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 207

Registration Number: NCT00760877

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy